ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Position Raised by Ameriprise Financial Inc.

Ameriprise Financial Inc. lifted its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 113.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 69,376 shares of the company's stock after acquiring an additional 36,928 shares during the quarter. Ameriprise Financial Inc. owned 0.07% of ARS Pharmaceuticals worth $732,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Alliancebernstein L.P. increased its holdings in ARS Pharmaceuticals by 5,168.4% in the fourth quarter. Alliancebernstein L.P. now owns 3,880,734 shares of the company's stock valued at $40,942,000 after buying an additional 3,807,074 shares during the last quarter. Vanguard Group Inc. increased its holdings in ARS Pharmaceuticals by 3.5% in the fourth quarter. Vanguard Group Inc. now owns 3,464,952 shares of the company's stock valued at $36,555,000 after buying an additional 115,656 shares during the last quarter. Alyeska Investment Group L.P. increased its holdings in ARS Pharmaceuticals by 903.0% in the fourth quarter. Alyeska Investment Group L.P. now owns 1,253,724 shares of the company's stock valued at $13,227,000 after buying an additional 1,128,724 shares during the last quarter. Geode Capital Management LLC increased its holdings in ARS Pharmaceuticals by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 1,238,156 shares of the company's stock valued at $13,066,000 after buying an additional 3,351 shares during the last quarter. Finally, Royce & Associates LP increased its holdings in ARS Pharmaceuticals by 34.4% in the fourth quarter. Royce & Associates LP now owns 929,613 shares of the company's stock valued at $9,807,000 after buying an additional 238,158 shares during the last quarter. 68.16% of the stock is owned by institutional investors.

Insider Transactions at ARS Pharmaceuticals

In other news, insider Alexander A. Fitzpatrick sold 102,969 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $14.10, for a total transaction of $1,451,862.90. Following the completion of the transaction, the insider now directly owns 89,613 shares in the company, valued at approximately $1,263,543.30. The trade was a 53.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Kathleen D. Scott sold 50,000 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $14.10, for a total value of $705,000.00. Following the sale, the chief financial officer now directly owns 7,424 shares in the company, valued at approximately $104,678.40. The trade was a 87.07% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 382,571 shares of company stock worth $5,177,904. Company insiders own 33.50% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have commented on SPRY shares. Scotiabank started coverage on ARS Pharmaceuticals in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 target price for the company. Oppenheimer started coverage on ARS Pharmaceuticals in a research note on Monday, February 10th. They issued an "outperform" rating and a $40.00 target price for the company. Wall Street Zen downgraded ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Finally, William Blair restated an "outperform" rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $31.00.

ARS Pharmaceuticals Price Performance

Shares of NASDAQ SPRY traded down $0.71 during midday trading on Wednesday, hitting $13.82. 847,793 shares of the company's stock were exchanged, compared to its average volume of 1,272,030. The stock's 50 day moving average price is $13.89 and its 200-day moving average price is $12.81. The firm has a market cap of $1.36 billion, a P/E ratio of -27.10 and a beta of 0.84. ARS Pharmaceuticals, Inc. has a twelve month low of $7.55 and a twelve month high of $18.51.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.35). The business had revenue of $7.97 million for the quarter, compared to analyst estimates of $7.48 million. On average, analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current fiscal year.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.